Rotation_CollagenImplant_WEB.png

Rotation Medical Announces Key Events at Arthroscopy Association of North America Annual Meeting

Posted On May 10, 2017 By OrthoSpineNews In Sports Medicine, Top Stories /  

May 09, 2017

PLYMOUTH, Minn.–(BUSINESS WIRE)–Rotation Medical Inc., a medical device company focused on developing new technologies to treat rotator cuff disease, today announced key events for the upcoming Arthroscopy Association of North America Annual Meeting May 18-20 in Denver. These events include first-ever presentation of results of the REBUILD study of the company’s Bioinductive Implant for rotator cuff repair, as well as multiple podium presentations.

Rotation Medical’s REBUILD (Rotation MEdical BioindUctive ImpLant Database) is a prospective, non-randomized, real-world registry study designed to collect patient-reported outcomes, including shoulder function, pain and quality of life, after receiving the Bioinductive Implant. Dr. Louis McIntyre of Northwell Health Physician Partners Orthopaedic Institute at Sleepy Hollow (New York) will share results of the first 200 patients enrolled in the study, as well as provide case examples and an overview of published clinical data on Thursday, May 18, 11:40 a.m. to 12:30 p.m.

Attendees will also have the opportunity to learn more about the Rotation Medical Bioinductive Implant at the following events:

  • Clinical Case Panel #1: Rotator Cuff. Dr. Jeffrey Abrams of Princeton Orthopaedic Associates (New Jersey) will highlight his use of the Bioinductive Implant. Thursday, May 18, 10:20-10:50 a.m.
  • Symposium 1: The Failed Cuff, What Now? Dr. Michael O’Brien of Tulane Institute of Sports Medicine (Louisiana) will discuss patch options and results. Thursday, May 18, 10:50-11:30 a.m.
  • The Holy Grail: Can We Successfully Treat the Overhead Athlete? Expert Advice and Experience. Dr. Michael T. Freehill of Michigan Medicine Orthopaedic Sports Medicine will highlight his use of the Bioinductive Implant. Thursday, May 18, 4:45-6:15 p.m.
  • State of the Art Grafts and Patches in Rotator Cuff Surgery: Augmentation, Interpositions, Superior Capsular Reconstruction and Bioinductive Implant. Dr. Richard Ryu of the Ryu Hurvitz Orthopedic Clinic (California) and Dr. Matthew T. Provencher of The Steadman Clinic and Steadman Philippon Research Institute (Colorado) will present the biology and mechanics of rotator cuff patches and grafts, including the surgical technique for the Bioinductive Implant. Friday, May 19, 7:45-9:15 a.m.
  • Feature Lecture #8: Patch Options and Results. Dr. Ryu will also provide an overview of the Bioinductive Implant for full thickness and partial tears. Friday, May 19, 3:15-3:30 p.m.

“Given the high failure rate and difficult recovery required for traditional approaches to rotator cuff repair, we believe the results of our REBUILD real-world study will speak to the potential of our Bioinductive Implant to transform the treatment of rotator cuff disease,” said Martha Shadan, president and CEO of Rotation Medical. “Attendees at this year’s AANA Annual Meeting will also have many opportunities to hear from their peers how our Bioinductive Implant can improve outcomes for people with rotator cuff tears.”

About Rotator Cuff Tears

Rotator cuff damage is the most common source of shoulder pain, affecting more than 4 million people annually in the U.S. Traditional approaches to treating degenerate or torn rotator cuffs often do not address the poor quality of the underlying tendon tissue, and a significant number of these tendons, after standard treatment, either degenerate further and/or re-tear.

About the Rotation Medical BioInductive Implant

Cleared by the U.S. Food and Drug Administration in March 2014, the Rotation Medical Bioinductive Implant is designed to address both the biomechanics and biology required to heal a rotator cuff tendon tear by inducing new tissue growth at the site of implantation, resulting in increased tendon thickness and healing of tendon defects with new tissue growth. The collagen-based implant is about the size of a postage stamp and it is part of the Rotation Medical rotator cuff system, which also includes disposable instruments that allow the arthroscopic procedure to be performed easily and quickly. For important safety information, visit http://rotationmedical.com/our-solution/risks/.

About Rotation Medical

Rotation Medical Inc. was founded in 2009 and is committed to improving the treatment of rotator cuff disease with the Rotation Medical rotator cuff system, a breakthrough technology that has the potential to prevent rotator cuff disease progression and reduce re-tears by inducing the growth of new tendinous tissue. The company is privately held and funded by New Enterprise Associates (NEA), Life Sciences Partners (LSP) and Pappas Ventures. For more information, visit http://www.rotationmedical.com/.

Contacts

Merryman Communications
Joni Ramirez
323-532-0746
joni@merrymancommunications.com

Read More
Meniscus_NusurfaceMeniscusImplant_WEB.jpg

Advanced Orthopedics & Sports Medicine Specialists Performs First Meniscus Replacements in Colorado

Posted On April 28, 2017 By OrthoSpineNews In Sports Medicine /  

April 27, 2017

DENVER–(BUSINESS WIRE)–Advanced Orthopedics & Sports Medicine Specialists, a regional leader in comprehensive orthopedic services, and Active Implants, a company that develops orthopedic implant solutions, today announced that the first meniscus replacement procedures in Colorado have been successfully performed by Dr. Wayne Gersoff. Advanced Orthopedics & Sports Medicine Specialists is the only center in Denver – and one of just 10 sites nationwide – enrolling patients with persistent knee pain caused by injured or deteriorating meniscus cartilage in the SUN trial, which is designed to assess the safety and effectiveness of the NUsurface® Meniscus Implant (pronounced “new surface”) in restoring function similar to that of a natural, healthy meniscus.

The recipient of the implant was 58-year-old Golden resident Kathleen Cohan, who tore her meniscus on both knees during a head-on collision over 35 years ago. Although she underwent two partial meniscectomies to treat the tears, she continued to experience knee pain. The pain became so severe that over the last six years, Cohan has dealt with constant burning and stiffness in her knees. As an avid backcountry skier, she was forced to cut down her skiing from 60 days to only two days a year. She was unable to go hiking, rock climbing or even walk for more than three miles. Cohan’s pain had persisted to the point where she had to take painkillers on an almost daily basis.

The meniscus is a tissue pad between the thigh and shin bones. Once damaged, the meniscus has a very limited ability to heal. Over 1 million partial meniscectomies to remove or repair a torn meniscus are performed in the U.S. every year, about the same as the total number of hip and knee replacement surgeries combined. However, many patients still experience persistent knee pain following meniscus surgery.

“There are limited options for patients who experience persistent knee pain following meniscus surgery,” Dr. Gersoff said. “Our hope with the NUsurface implant is that it will alleviate pain in these patients, helping them to delay or avoid knee replacement surgery, and allowing them to return to the activities they enjoy.”

Cohan received the NUsurface Meniscus Implant on May 21, 2016, through a small incision in her right knee and completed a six-week rehabilitation program. It has been almost one year since her surgery and the constant burning pain in her right knee has fully subsided. In addition to her daily leisure activities, she has even returned to backcountry skiing and hiking on a regular basis. Most recently, Cohan went on an adventure trip in Costa Rica with a stable knee, which included rough and steep walking surfaces, class IV river rafting, zip lines and hanging bridges.

“Receiving the NUsurface Meniscus Implant has really helped me return to my active sports lifestyle,” Cohan said. “Avoiding joint replacement is very important to me, and I am hopeful that this implant will help me delay knee replacement for another 10 years.”

The NUsurface Meniscus Implant has been used in Europe under CE Mark since 2008 and Israel since 2011.

About the Clinical Trial

The SUN study (Safety Using NUsurface®) will enroll approximately 120 patients as part of regulatory process to gain approval from FDA to sell the device in the U.S. All patients who meet study requirements and agree to enter the trial are offered the NUsurface Meniscus Implant as treatment. Treatment with NUsurface in the SUN trial is eligible for coverage by Medicare and some private insurance companies. To be eligible for the study, participants must be between the ages of 30 and 75 and have pain after medial meniscus surgery that was performed at least six months ago. To learn more about the SUN study, please visit http://sun-trial.com or call (844) 680-8951.

About the NUsurface® Meniscus Implant

The NUsurface® Meniscus Implant is an investigational treatment for patients with persistent knee pain following medial meniscus surgery. It is made from medical grade plastic and, as a result of its unique materials, composite structure and design, does not require fixation to bone or soft tissues. The NUsurface Meniscus Implant mimics the function of the natural meniscus and redistributes loads transmitted across the knee joint. Clinical trials are underway in the U.S., Europe and Israel to verify the safety and effectiveness of the NUsurface Meniscus Implant.

About Advanced Orthopedic and Sports Medicine Specialists

Advanced Orthopedic and Sports Medicine Specialists is widely recognized as the regional leader in comprehensive orthopedic services. The physicians of Advanced Orthopedic and Sports Medicine Specialists have received specialized training in orthopedic surgery and in subspecialty areas within the field of orthopedic medicine. Advanced Orthopedic and Sports Medicine Specialists specializes in providing comprehensive sports medicine services including the diagnosis and treatment of athletic injuries. We now have 9 Orthopedic Surgeons, 2 Podiatric Surgeons and 1 Board Certified Interventional Physiatrist. Our practice is comprised of surgeons who specialize in sports injuries, upper extremity, spine disorders, total joint replacements, carticel implantation, podiatry abnormalities, musculoskeletal disorders, and surgical and non operative treatment of the neck and spine. Advanced Orthopedic and Sports Medicine Specialists has two locations which offer state of the art digital imaging: our Lowry Office in Central Denver and our Lincoln office located in South Denver. For more information, visit http://www.advancedortho.org/ or call our main office at (303) 344-9090.

About Active Implants

Active Implants, LLC develops orthopedic implant solutions that complement the natural biomechanics of the musculoskeletal system, allowing patients to maintain or return to an active lifestyle. Active Implants is privately held with headquarters in Memphis, Tennessee. European offices are in Driebergen, The Netherlands, with R&D facilities in Netanya, Israel. For more information, visit www.activeimplants.com.

CAUTION Investigational device. Limited by United States law to investigational use.

Contacts

For Active Implants, LLC
Joni Ramirez, 323-532-0746
joni@merrymancommunications.com

Read More
xm_p5135169.jpg.pagespeed.ic_.rXaTias2lg.jpg

Northwell Announces Affiliation Agreement With Acclaimed Orthopedic Institute

Posted On April 20, 2017 By OrthoSpineNews In Extremities, Sports Medicine, Top Stories /  

NEW HYDE PARK, N.Y., April 20, 2017 /PRNewswire-USNewswire/ — Northwell Health has signed a strategic affiliation agreement with the Rothman Institute, one of the nation’s largest, most-prestigious orthopedic practices.

Headquartered in Philadelphia, Pennsylvania, Rothman Institute is known internationally as a preeminent orthopedic and musculoskeletal practice, with more than 25 locations throughout Pennsylvania and New Jersey, including two orthopedic urgent care clinics.  Rothman Institute is recognized for their innovative treatment methods, research, education and technology.

The Northwell Health Orthopaedic Institute will be working with Rothman Institute to develop centers of excellence for orthopedic care in the New York Metropolitan area, including Manhattan.

“We’re excited about the affiliation with the Rothman Institute,” said Nicholas Sgaglione, MD, chair of orthopedics at Northwell Health. “The affiliation will bring together two nimble, forward-thinking organizations that emphasize high-quality care. We also look forward to working with the Rothman Institute to co-brand various marketing initiatives, the ongoing recruitment of top-level physicians, joint research, and tracking and measuring patient outcomes.”

“We look forward to joining the Northwell Health family,” said Alexander R. Vaccaro, MD, PhD, MBA, president of Rothman Institute, Richard H. Rothman Professor and chairman of the Department of Orthopaedics, and professor of neurosurgery at Thomas Jefferson University and Hospitals. “This agreement expands Rothman Institute’s footprint into New York City and the surrounding suburbs. We are looking forward to bringing our excellent musculoskeletal care to Northwell Health’s communities and patients now and for years to come.”

About Northwell Health
Northwell Health is New York State’s largest health care provider and private employer, with 21 hospitals and over 550 outpatient practices. We care for more than two million people annually in the metro New York area and beyond, thanks to philanthropic support from our communities. Our 61,000 employees – 15,000+ nurses and nearly 3,400 physicians, including nearly 2,700 members of Northwell Health Physician Partners – are working to change health care for the better. We’re making breakthroughs in medicine at the Feinstein Institute. We’re training the next generation of medical professionals at the visionary Hofstra Northwell School of Medicine and the School of Graduate Nursing and Physician Assistant Studies. And we offer health insurance through CareConnect. For information on our more than 100 medical specialties, visit Northwell.edu.

About Rothman Institute
Rothman Institute is a private orthopaedic practice dedicated to providing communities with high-quality, compassionate, and affordable musculoskeletal care that is grounded in evidence-based medicine, the results of which will exceed expectations. Rothman Institute orthopaedists treat patients at over 25 locations in the Philadelphia-region, including orthopaedic urgent care clinics in Marlton, NJ and Limerick, PA.

With experts in orthopaedic sub-specialties including spine, hip and knee, foot and ankle, shoulder and elbow, hand and wrist, sports medicine, physical medicine and  rehabilitation, orthopaedic oncology and trauma, Rothman Institute is internationally recognized for excellence in clinical treatment  methods, research, education and technology. Consistently recognized as national and regional “Top Docs,” Rothman Institute is proud to be the first practice serving as official team physicians for all four of the major professional sports teams in one city, the Philadelphia Eagles, Phillies, Flyers and 76ers, as well as over 40 college and high school teams. For more information about Rothman Institute please call 1-800-321-9999 or visit www.RothmanInstitute.com.

SOURCE Northwell Health

Related Links

https://www.northwell.edu

Read More
stem-cell-spinal_cord.jpg

InVivo Therapeutics Announces Oral Presentations at the 2017 American Spinal Injury Association Annual Scientific Meeting

Posted On April 20, 2017 By OrthoSpineNews In Neuro, Sports Medicine /  

April 20, 2017

CAMBRIDGE, Mass.–(BUSINESS WIRE)–InVivo Therapeutics Holdings Corp. (NVIV) today announced that the company will be giving two oral presentations at the 2017 American Spinal Injury Association (ASIA) Annual Scientific Meeting to be held April 26-29, 2017 in Albuquerque, New Mexico. Alex Aimetti, Ph.D., Vice President, Medical Education and Scientific Support, will present a clinical trial update during the “Clinical Trials 360-degree” session sponsored by Spinal Cord Outcomes Partnership Endeavor (SCOPE) on Friday, April 28. Dr. Aimetti will also present an abstract entitled “Relationship of ASIA Impairment Scale (AIS) Grade to Post-injury Hospitalization Costs in Thoracic Spinal Cord Injury” during a general session on Saturday, April 29. The abstract is co-authored by Dr. Aimetti, Ellen Dukes, Ph.D., Steven Kirshblum, M.D., Sarah Qin, M.B.A., Rebecca Bornheimer, B.A., and Gerry Oster, Ph.D. In addition to the two oral presentations, the company will have an exhibit booth at the meeting.

Mark Perrin, Chairman and CEO, said, “The American Spinal Injury Association Annual Scientific Meeting will allow us to continue to strengthen and expand our relationships within the spinal cord injury research and care network, and we look forward to having a significant presence at this meeting. We are also pleased to be providing an update on our clinical program, especially given our significant progress throughout the start of this year.”

About the Neuro-Spinal Scaffold™ Implant

Following acute spinal cord injury, surgical implantation of the biodegradable Neuro-Spinal Scaffold within the decompressed and debrided injury epicenter is intended to support appositional healing, thereby reducing post-traumatic cavity formation, sparing white matter, and allowing neural regeneration across the healed wound epicenter. The Neuro-Spinal Scaffold, an investigational device, has received a Humanitarian Use Device (HUD) designation and currently is being evaluated in The INSPIRE Study for the treatment of patients with acute, complete (AIS A), thoracic traumatic spinal cord injury and a pilot study for acute, complete (AIS A), cervical (C5-T1) traumatic spinal cord injury.

About InVivo Therapeutics

InVivo Therapeutics Holdings Corp. is a research and clinical-stage biomaterials and biotechnology company with a focus on treatment of spinal cord injuries. The company was founded in 2005 with proprietary technology co-invented by Robert Langer, Sc.D., Professor at Massachusetts Institute of Technology, and Joseph P. Vacanti, M.D., who then was at Boston Children’s Hospital and who now is affiliated with Massachusetts General Hospital. In 2011, the company earned the David S. Apple Award from the American Spinal Injury Association for its outstanding contribution to spinal cord injury medicine. In 2015, the company’s investigational Neuro-Spinal Scaffoldreceived the 2015 Becker’s Healthcare Spine Device Award. The publicly-traded company is headquartered in Cambridge, MA. For more details, visit www.invivotherapeutics.com.

Safe Harbor Statement

Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements within the meaning of the federal securities laws. These statements can be identified by words such as “believe,” “anticipate,” “intend,” “estimate,” “will,” “may,” “should,” “expect,” “designed to,” “potentially,” and similar expressions, and include statements regarding the safety and effectiveness of the Neuro-Spinal Scaffold and the progress of the clinical program. Any forward-looking statements contained herein are based on current expectations, and are subject to a number of risks and uncertainties. Factors that could cause actual future results to differ materially from current expectations include, but are not limited to, risks and uncertainties relating to the company’s ability to successfully open additional clinical sites for enrollment and to enroll additional patients; the timing of the Institutional Review Board process; the company’s ability to commercialize its products; the company’s ability to develop, market and sell products based on its technology; the expected benefits and efficacy of the company’s products and technology in connection with the treatment of spinal cord injuries; the availability of substantial additional funding for the company to continue its operations and to conduct research and development, clinical studies and future product commercialization; and other risks associated with the company’s business, research, product development, regulatory approval, marketing and distribution plans and strategies identified and described in more detail in the company’s Annual Report on Form 10-K for the year ended December 31, 2016, and its other filings with the SEC, including the company’s Form 10-Qs and current reports on Form 8-K. The company does not undertake to update these forward-looking statements.

Contacts

InVivo Therapeutics Holdings Corp.
Heather Hamel, 617-863-5530
Investor Relations
Investor-relations@invivotherapeutics.com

Read More
mma.prnewswire.comHSS_Ambulatory_Surgery_Ce-2f9fe533a85ce996cd3674405f97a53377f77230.jpg

HSS Opens Ambulatory Surgery Center in Manhattan

Posted On April 12, 2017 By OrthoSpineNews In Extremities, Sports Medicine /  

NEW YORK, N.Y., April 12, 2017 /PRNewswire-USNewswire/ — Today, Hospital for Special Surgery (HSS) the first and only hospital in the United States dedicated to orthopedic and rheumatologic care, announced its plan to open the HSS ASC of Manhattan in June 2017.

The HSS ASC of Manhattan will focus on hand, foot and ankle and sports medicine surgeries. David S. Levine, MD, foot and ankle surgeon at HSS, will serve as the center’s medical director.

“The HSS ASC of Manhattan is a very exciting initiative,” said Dr. Levine. “This new location and offering will substantially expand access to ambulatory surgery as an extension of Hospital for Special Surgery.”

The 22,425 square-foot center is conveniently located at 1233 Second Avenue at 65th Street, a short distance from the Hospital main campus. The center features four operating rooms and a 16 bay pre- and post-surgical unit.

“For nearly three decades HSS has been leading the fields of orthopedics and rheumatology in quality and patient experience,” said Louis A. Shapiro, president and CEO, Hospital for Special Surgery. “HSS is more than a hospital and we’re constantly working to identify news ways to make better quality care more accessible, through research, innovation and locations like this new ASC.”

Bryan Guss, RN, BSN, CNOR, will be the new senior director of the ASC and is joining HSS from Northern Westchester Hospital. HSS physicians on staff at the ASC will include ten sports medicine specialists, five foot and ankle surgeons and five hand and upper extremity surgeons. In addition to the 20 specialty surgeons, there will be anesthesiologists and nursing professionals providing care to patients.

Ambulatory surgery cases will still be performed at the HSS main campus. The HSS ASC of Manhattan is optimizing the care delivery system by providing another surgical location option for patients.

About Hospital for Special Surgery
Hospital for Special Surgery (HSS) is the world’s leading academic medical center focused on musculoskeletal health. HSS is nationally ranked No. 1 in orthopedics and No. 2 in rheumatology by U.S. News & World Report (2016-2017), and is the first hospital in New York State to receive Magnet Recognition for Excellence in Nursing Service from the American Nurses Credentialing Center four consecutive times. HSS has one of the lowest infection rates in the country. HSS is an affiliate of Weill Cornell Medical College and as such all Hospital for Special Surgery medical staff are faculty of Weill Cornell. The Hospital’s research division is internationally recognized as a leader in the investigation of musculoskeletal and autoimmune diseases. Hospital for Special Surgery is located in New York City and online at www.hss.edu.

 

SOURCE Hospital for Special Surgery

Related Links

http://www.hss.edu

Read More
kfx.jpg

KFx Medical, LLC Announces Another and Third License of its Knotless Double Row Patents

Posted On April 7, 2017 By OrthoSpineNews In Regulatory, Sports Medicine /  

April 06, 2017

SAN DIEGO–(BUSINESS WIRE)–KFx Medical, LLC announced that it has entered into a license agreement with CONMED Corporation – CNMD (NASDAQ) relating to its patents used in knotless double row rotator cuff repair.

Under the agreement, CONMED and its affiliates will have the right to promote the use of products and techniques for knotless double row rotator cuff repair as claimed in US Patent number 7,585,311 and related patents and applications for the life of those patents. Approximately one-third of more than 400,000 rotator cuff repairs in the United States utilize the technique to achieve an anatomic reattachment of tendon.

Terms of the licensing agreement were not disclosed.

“We are proud to have our innovation recognized by CONMED. Previously we announced our licensing agreements with Smith & Nephew, Inc. and Mitek, a Johnson & Johnson Company for the same patents. I am pleased with the licensing arrangement with these three world leaders and knowing KFx’s valuable double row knotless rotator cuff technology will reach even more patients,” indicated Tate Scott, President and Chief Executive Officer.

About KFx Medical, LLC

KFx Medical LLC was founded in 2003 to develop products for tissue fixation in a variety of orthopedic surgical procedures performed on the shoulder, knee, foot, and ankle. KFx provides simple systems for orthopedic surgeons focused on sports medicine. The company is privately held. Investors include Alloy Ventures, Charter Life Sciences, Arboretum Ventures, Montreux Equity Partners, and MB Venture Partners.

Contacts

KFx Medical
W. Tate Scott, 619-742-2010
Tate.Scott@KFxmed.com

Read More
2266d52.png

CollPlant Provides Commercial and Operational Update

Posted On March 30, 2017 By OrthoSpineNews In Biologics, Sports Medicine /  

NESS ZIONA, Israel, March 30, 2017 /PRNewswire

CollPlant (TASE: CLPT), a regenerative medicine company utilizing its proprietary plant-based rhCollagen technology for tissue repair products (recombinant human, “rhCollagen”), today provided a commercial and operational update in its annual reports.

Most recently, in November 2016, the Company announced the signing of an exclusive distribution agreement with Arthrex GMBH to distribute Vergenix™STR, CollPlant’s CE Mark-approved treatment for tendinopathy, in Europe, and has supplied Arthrex with first orders. Arthrex, an affiliate of Arthrex Inc., based in Naples, FL, is a leading orthopedics company and is widely considered to be the world leader in sports medicine. Additionally, since mid-2016, CollPlant signed a number of marketing agreements for Vergenix™FG, its wound care product, covering Italy, Switzerland and Turkey. Commercial treatments have been completed over several months in Switzerland and Italy, and physicians’ feedback regarding patient results have been very positive.

CollPlant has also reported extensively for the first time on the development of its collagen-based biological ink, bioInk, for use in 3D printing of organs and tissues. Specifically, the Company is developing rhCollagen-based bioInk formulations for indications including skin, orthopedics, ophthalmology, heart and lung. The Company’s goal for the coming year includes working with a strategic international partner to further develop a specific indication of this product.

CollPlant’s Highlights for 2016 and the start of 2017

  • Vergenix™FG – a wound filler based on the Company’s rhCollagen technology, for treatment of acute and chronic wounds: The product received CE Mark approval and distribution agreements have been signed in Italy, Switzerland and Turkey, including first orders, a portion of which were supplied in 2016. The initial target market for Vergenix™FG is estimated at $500 million annually. The Company has received positive feedback from physicians who have treated patients with the product in Europe.
  • Vergenix™STR – a gel based on the Company’s rhCollagen technology, indicated for the treatment of tendinopathy: The product was granted CE Mark approval following successful clinical trials, and an exclusive distribution agreement was signed with Arthrex covering Europe, India and Africa. To date, CollPlant has reported on two orders supplied to Arthrex, and the product is currently in the initial stages of penetrating the European market. First treatments have commenced in Europe. The target market for Vergenix™STR is estimated at about three million procedures per annum worldwide, with a value of $2 billion.
  • BioInk for 3D printing of organs and tissues – the Company is developing a biological ink (bioInk) based on its rhCollagen technology, intended for use with 3D printers, to print tissues and organs. In parallel, the Company is assessing potential joint ventures with international companies to further develop various applications such as skin, bones, ophthalmology, heart and lungs. The Company’s objective for this year is the development of a specific indication in order to achieve the creation of multilayer tissue combined with stem cells and other cells.  The segment of 3D printing addresses the entire global medical market.

About CollPlant

CollPlant is a regenerative medicine company leveraging its proprietary, plant-based recombinant human collagen (rhCollagen) technology for the development and commercialization of tissue repair products, initially for the orthobiologics and advanced wound care markets. The Company’s cutting-edge technology is designed to generate and process proprietary rhCollagen, among other patent-protected recombinant proteins. Given that CollPlant’s rhCollagen is identical to the type I collagen produced by the human body, it offers significant advantages compared to currently marketed tissue-derived collagen, including improved biofunctionality, superior homogeneity and reduced risk of immune response. The Company’s broad development pipeline includes biomaterials indicated for orthopedics and advanced wound healing. Lead products include: Vergenix™STR (Soft Tissue Repair Matrix), for the treatment of tendinopathy; and Vergenix™FG (Flowable Gel) wound filler, for treatment of acute and chronic wounds. CollPlant’s business strategy includes proprietary development and manufacture of tissue repair products and their commercialization and distribution, together with leading third parties, alongside alliances with leading companies for joint development, manufacture and marketing of additional products.

For more information about CollPlant, visit http://www.collplant.com

Contact at CollPlant:
Eran Rotem
Chief Financial Officer
Tel: +972-73-2325600/612
Email: Eran@collplant.com
Contact at Rx Communications Group, LLC
Paula Schwartz (for US Investors)
Senior Vice President
Tel: +1-917-322-2216
Email: pschwartz@rxir.com

SOURCE CollPlan

Read More
Sports-Medicine_Content.jpg

Sports Medicine Devices Market Worth US$ 9.3 billion Globally by 2022

Posted On March 27, 2017 By OrthoSpineNews In Financial, Sports Medicine /  

Press release from: Market Research Engine Research Reports

New York, March 24: Market Research Engine has published a new report titled as “Sports Medicine Devices Market By Product Analysis (Accessories, Body Evaluation and Monitoring, Body Repair and Reconstruction, Support and Recovery Products, Orthopedic Products); By Application Analysis (Hand-wrist, Ankle-foot, Shoulders, Arm-elbow, Back-spine, Knee, Hip-groin) and By Regional Analysis – Global Forecast by 2016 – 2022”

How Big is the Global Sports Medicine Devices Market?

The Global Sports Medicine Devices Market is expected to exceed more than US$ 9.3 billion by 2022 and will grow at a CAGR of more than 8% in the given forecast period.

www.marketresearchengine.com/reportdetails/sports-medicin…

Sports medicine is a branch of medication that offers with the prevention and treatment of injuries incurred at some point of sports activities sports, physical activities or bodily fitness education. Sports activities medicine devices consequently, consist of a huge range of goods applied for the prevention, recovery and treatment of accidents related to the above physical sports. Those injuries encompass fractures, sprains, tender tissue harm, joint dislocation, strain and musculoskeletal injuries. The increased global adoption of western sports has given upward thrust to accidents that power the market for sports medicinal drug devices.

The major driving factors of Global Sports Medicine Devices Market are as follows:

• Increasing demand for outpatient
• Increasing awareness regarding the maintenance of an active lifestyle
• Minimally invasive surgeries
• Changing re-imbursement landscape for new surgical technologies

 

READ THE REST HERE

Read More
Ortho-Regenerative-Technologies-Inc-2.jpg

Ortho Regenerative technology platform front and center at 2017 ORS Annual Meeting

Posted On March 27, 2017 By OrthoSpineNews In Sports Medicine /  

KIRKLAND, QC, March 24, 2017 /CNW Telbec/ – Ortho Regenerative Technologies Inc. (“Ortho RTi” or the “Company”), an emerging Orthopaedic and Sports Medicine Technology company, today announced that the results of four key scientific studies validating its product’s ability to improve the repair of three distinct joint tissues – the rotator cuff tendons, the meniscus and articular cartilage – were presented at the Annual Orthopaedic Research Society (“ORS”) (http://www.ors.org) meeting.

The ORS Annual Meeting attracts over 3,000 attendees with an interest in Orthopaedic research including clinicians, surgeons, residents, veterinarians, basic scientists, and engineers who present the latest innovative and cutting-edge musculoskeletal research. This year’s ORS Annual Meeting was held this week in San Diego, CA.

The first presentation described a pilot study designed to examine the feasibility of applying the Company’s proprietary Ortho-R implants in conjunction with suturing to improve rotator cuff repair. The researchers found that Ortho-R implants in conjunction with transosseous suturing improved histological structure at the supraspinatus tendons insertion site compared to suturing alone.

The second presentation was entitled “Freeze-dried chitosan-PRP injectable surgical implants for meniscus repair: results from pilot ovine studies.” This presented study findings that the Company’s proprietary Ortho-R implants showed superior regenerative effect over wrapping the meniscus with a collagen membrane or PRP alone, indicating that Ortho-R implants have the potential to overcome some of the current limitations of meniscus repair.

The third presentation, entitled “Freeze dried chitosan/platelet-rich-plasma implants improve marrow stimulated cartilage repair in rabbit chronic defect model”, described a study that was designed to evaluate the augmentation of Bone Marrow Stimulation (“BMS”) with the Company’s proprietary Ortho-R implants. This presentation concluded that augmentation by Ortho-R implant improves the highly variable and less than adequate repair elicited by BMS augmented with PRP, especially in challenging and hard to treat sites.

A fourth presentation highlighted scientific results related to how various surgical procedures in the knee joint may lead to changes in meniscus inter-tie coil morphology and, thereby, affect peripheral pain.

“We believe that increasing researcher and clinician awareness of our proprietary biopolymer platform through our participation in important scientific meetings like ORS will go a long way towards advancing the technology’s development and eventual product adoption,” said Dr. Michael Buschmann, CSO of Ortho RTi. “This type of third-party scientific validation, where four of our studies were reviewed by external experts and selected for broad exposure at this, the most important event of its kind worldwide, is incredibly energizing.”

Dr. Buschmann concluded, “It attests to the progress and excitement we are making towards validating our product for use in healing these types of injuries.”

Forward-Looking Statements

This news release may contain certain forward-looking statements regarding the Corporation’s expectations for future events. Such expectations are based on certain assumptions that are founded on currently available information. If these assumptions prove incorrect, actual results may differ materially from those contemplated by the forward-looking statements contained in this press release. Factors that could cause actual results to differ include, amongst others, uncertainty as to the final result and other risks. The Corporation disclaims any intention or obligation to publicly update or revise any forward- looking statements, whether as a result of new information, future events or otherwise, other than as required by security laws.

About Ortho Regenerative Technologies Inc.

Ortho RTi is an emerging Orthopaedic and Sports Medicine technology company dedicated to the development of novel therapeutic tissue repair devices to dramatically improve the success rate of sports medicine surgeries.  We are committed to improving patients’ lives through increasing the success rates of surgeries for soft tissue injuries. Our proprietary biopolymer has been specifically designed to increase the healing rates of sports related injuries to ligaments, tendons and cartilage. The polymer can be directly placed into the site of injury by a surgeon during a routine operative procedure without significantly extending the time of the surgery and without further intervention.  Visit us on the internet at www.orthorti.com.

Read More
9477197.png

It’s not magic; it’s science

Posted On March 17, 2017 By OrthoSpineNews In Extremities, Sports Medicine /  

Steve Collins, Contributor – CFO/COO Oska, Inc.

If you suffer from chronic pain, it’s likely you’ve chased rainbows, been let down by false marketing claims or – at worst – lost hope that anything will emerge to help manage your pain effectively. Additionally, you’ve probably spent considerable amounts purchasing items that just don’t perform as stated. Sadly, for those suffering, things are getting worse. Recent Centers for Disease Control policies have emphasized prescribing less opiate pain-killers and the Drug Enforcement Administration has announced it intends listing kratom, an herbal pain-relief supplement, as a “schedule I” substance. This means that whether you are currently using prescribed narcotic pain-killers, or an herbal substitute, you will have no choice but to identify and use other pain-relief options.

The human body is wondrous, and its capacity to heal itself is amazing. Think of a scraped knee, bruised heel or sprained ankle. The body’s own healing processes kick in automatically in response to injuries. Chronic pain, however, is more challenging to manage. Most times, because chronic pain exists in localized unstable body areas, the natural healing processes need a kick-start. TENs devices, creams, pharmaceuticals and even physical therapy tend to be effective, but only for short periods as they “interrupt” pain rather than actually addressing the source. Ask any doctor or physical therapist the key to recovery, and most will say “exercise”. But if you already experience pain, the mere thought of exercise may fill you with anxiety.

What if it was possible to exercise an injury without leaving your chair, touching your toes or wrestling with a physiotherapist? What if there was an alternative option to swallowing dangerous narcotic or analgesic pain-killers?

Have you ever heard of pulsed electromagnetic field therapy (PEMF)?

PEMF, as a science, has been used for over 60 years with no known adverse effects. NASA uses it as an effective means of countering bone-density loss and muscle atrophy in astronauts exposed to weightless environments for prolonged periods. In fact, it is so effective that the FDA has cleared PEMF to close bone fractures, for mitigating migraines and for orthodontic work. If you think an electromagnetic field sounds “wacky”, consider that Earth generates one and so does your body!

PEMF emits very low-frequency waves that are created many times each second. These waves push and pull on human cells causing them to squeeze and stretch. As a result, cells can breathe more easily, allowing important healing signals to be carried into the cell. These signals then activate its natural recovery response and cause it to exhale even more healing signals into the surrounding area, promoting intensive healing. An injured area is typically not functioning normally, and if the healing process is compromised, pain can become chronic. When PEMF is introduced into the injured area, it acts at the cellular level to kick-start the body’s natural healing process.

A PEMF device produces similar effects as physical exercise, but you won’t feel anything. Typically, PEMF devices deliver three things: reduced pain levels; reduced inflammation; and improved range of motion. Whereas a TENs unit merely interrupts a pain signal, PEMF actually works at the cellular level, allowing for natural healing. Significantly, a PEMF device does not cause the usual discomfort experienced via a TENs unit because it is noninvasive (lacking physical attachment requirements) and is portable (you can use it at home, at work, in the car).

PEMF is a lesser-known therapy amongst consumers, but it provides scientifically superior results. It seems miracles can happen! CDC: we are looking at you!

 

READ MORE ABOUT OSKA HERE

 

 

Read More